Johnson & Johnson's IMAAVY Shows Promising Results for Myasthenia Gravis

By Simone Carter

Johnson & Johnson unveiled new findings from the Phase 3 Vivacity-MG3 study at the European Academy of Neurology (EAN) 2026 Congress on June 26. The data highlights the efficacy of IMAAVY (nipocalimab-aahu) in treating generalized myasthenia gravis (gMG), a chronic autoimmune neuromuscular disorder.

The study's post-hoc analyses demonstrated that patients early in their disease course (diagnosed within five years) experienced a significant reduction in Myasthenia Gravis–Activities of Daily Living (MG-ADL) scores when treated with nipocalimab combined with standard care. The mean reduction was −4.9 compared to −2.7 in the placebo group, with a statistically significant difference of −2.22 (p = 0.005).

Patients with a lower baseline symptom burden also showed improved outcomes. Those receiving nipocalimab had a mean MG-ADL score change of −4.5 versus −2.3 in the placebo group, and a Quantitative Myasthenia Gravis (QMG) score change of −5.2 versus −1.9, both statistically significant improvements.

In terms of safety, adverse events were reported in 84% of participants in both the nipocalimab and placebo groups. Serious adverse events were less frequent in the nipocalimab group (9%) compared to the placebo group (14%).

Additionally, the PETUNIA study was introduced to investigate outcomes of nipocalimab treatment during pregnancy, addressing a critical evidence gap.

IMAAVY is currently approved by the EMA and FDA as an add-on therapy for adult and adolescent patients with anti-AChR+ or anti-MuSK+ gMG.